GW Pharmaceuticals (GW Pharmaceuticals) EV-to-EBIT : -92.14 (As of May. 11, 2024)

GW Pharmaceuticals EV-to-EBIT Chart

GW Pharmaceuticals Annual Data
	Trend	Sep11	Sep12	Sep13	Sep14	Sep15	Sep16	Sep17	Sep18	Dec19	Dec20
EV-to-EBIT		Get a 7-Day Free Trial					-30.84	-14.19	-16.16	-336.93	-54.75

GW Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
EV-to-EBIT	Get a 7-Day Free Trial															61.71	-65.08	-45.13	-54.75	-87.53

Competitive Comparison of GW Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - General subindustry, GW Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GW Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GW Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where GW Pharmaceuticals's EV-to-EBIT falls into.

GW Pharmaceuticals EV-to-EBIT Calculation

GW Pharmaceuticals's EV-to-EBIT for today is calculated as:

GW Pharmaceuticals's current Enterprise Value is $6,398.0 Mil.
GW Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-69.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GW Pharmaceuticals  (NAS:GWPH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

GW Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2021 is calculated as:

GW Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2021 was $6,424.1 Mil.
GW Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-69.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GW Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of GW Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

GW Pharmaceuticals (GW Pharmaceuticals) Business Description